NewcelX Ltd.

NCEL chart

NewcelX Ltd. news

• NewcelX Ltd. Prices $1.55 Million Private Placement at $3.29 a Share

  www.tokenpost.com · Nov 10, 8:38 AM EST

• NewcelX Announces $1.55 Million Equity Financing at Premium

  TipRanks · Nov 9, 10:18 AM EST

• NewcelX prices $1.55M share offering at $3.29 to fund diabetes program

  TradingView · Nov 9, 10:09 AM EST

• NewcelX raises $1.55M via private placement at 20% premium

  Investing.com · Nov 9, 9:24 AM EST

• Investors agree to pay a 20% share-price premium in NewcelX (NCEL) financing.

  Stock Titan · Nov 9, 9:06 AM EST

• NewcelX raises $1.55M via private placement at 20% premium By Investing.com

  Investing.com UK · Nov 9, 9:06 AM EST

• NewcelX Announces Pricing of $1.55 Million Equity Financing at 20% Premium Pricing to Market

  Yahoo Finance · Nov 9, 9:00 AM EST

• NewcelX sells Mazindol assets to REA for equity, milestones

  Investing.com · Nov 4, 8:59 AM EST

• NewcelX Enters Binding Term Sheet to Divest Mazindol Portfolio

  TipRanks · Nov 4, 8:49 AM EST

• A proposed Mazindol sale would pay NewcelX (NCEL) $30K in cash plus a stake in the buyer.

  Stock Titan · Nov 4, 8:16 AM EST

• NewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone Payments

  Yahoo Finance · Nov 4, 8:00 AM EST

• NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes

  Yahoo Finance · Sep 28, 8:00 AM EDT

NewcelX Ltd. key financials

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-11-09
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-11-09
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-11-04
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-09-18
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-08-03
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-07-31
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-07-15
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-07-08
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-07-01
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-06-30
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-06-15
• 6-KCURRENT REPORT2026-06-05

About NewcelX Ltd.

Ticker

NCEL (Nasdaq)

Industry

Pharmaceutical Preparations

Headquarters

Zurich

Incorporated in

Switzerland

Fiscal year end

December 31

SEC CIK

1783036

Former names

NLS Pharmaceutics Ltd.

Frequently asked questions